FLGT - Company ID 0001674930
The table below shows Fulgent Genetics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $322.67M | $283.47M | $289.21M | $618.97M | $992.58M | $421.71M |
| Cost of revenue | $191.80M | $176.25M | $184.76M | $252.07M | $215.53M | $89.81M |
| Gross profit | $130.88M | $107.22M | $104.46M | $366.90M | $777.05M | $331.90M |
| R&D | $53.91M | $48.82M | $41.44M | $28.91M | $24.22M | $11.58M |
Fulgent Genetics, Inc. reported annual revenue of $322.67M for fiscal year 2025. That is up 13.8% from $283.47M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $18.28M (FY 2016) to $322.67M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $116.66M |
| $88.11M |
| $89.00M |
| $111.07M |
| $50.73M |
| $15.21M |
| Operating income | -$91.10M | -$73.92M | -$195.53M | $178.53M | $675.95M | $290.16M |
| Income tax | -$8.39M | -$8.14M | $1.15M | $42.10M | $174.79M | $72.53M |
| Net income | -$60.51M | -$42.71M | -$167.82M | $143.40M | $507.36M | $214.31M |
| EPS (diluted) | - | - | - | - | - | - |